Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment

ABSTRACT: Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment

PROVIDER: PRJNA831854 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18915600_1.fastq.gz	Fastqsanger.gz
	SRR18915600_2.fastq.gz	Fastqsanger.gz
	SRR18915601_1.fastq.gz	Fastqsanger.gz
	SRR18915601_2.fastq.gz	Fastqsanger.gz
	SRR18915602_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 80

Similar Datasets

Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment [miRNA-Seq]

Project description:Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment [miRNA-Seq]

| PRJNA831859 | ENA

Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment [RNA-Seq]

Project description:Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment [RNA-Seq]

| PRJNA831858 | ENA

Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment [RNA-Seq]

Project description:Two cohorts with cerebrovascular disease are included in the present study, i.e., SCD group and VCI group. Participants in SVD group has the normal cognitive function and others in VCI group show the worse cognitive function. The whole-blood is collected from each participant, and RNA sequencing is conducted in whole-blood samples. Characteristic of circRNA, lncRNA, miRNA and mRNA are identified in the present blood samples.

2022-04-28 | GSE201482 | GEO

Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment [miRNA-Seq]

2022-04-28 | GSE201481 | GEO

Characteristic of the transcriptomics in the early subcortical vascular cognitive impairment

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-04-28 | GSE201483 | GEO

Ginsenoside CK improves cognitive impairment

Project description:Ginsenoside CK improves cognitive impairment

| PRJNA916218 | ENA

Human amnion epithelial cell therapy reduces hypertension-induced vascular stiffening and cognitive impairment

Project description:Human amnion epithelial cell therapy reduces hypertension-induced vascular stiffening and cognitive impairment

| PRJNA1041469 | ENA

Identification of different miRNAs in Alzheimer's disease and vascular cognitive impairment and dementia

Project description:Identification of different miRNAs in Alzheimer's disease and vascular cognitive impairment and dementia

| PRJNA904393 | ENA

Identification of different miRNAs in Alzheimer's disease and vascular cognitive impairment and dementia

Project description:There are many subtypes of dementia without any minimally invasive, low-cost and efficient diagnostic biomarkers. MicroRNA (miRNA) are easily gained and accessible from patients, which may be a promising biomarker for dementia diagnosis and differential diagnosis. We make a completely expression analysis of serum miRNA from 24 participants including post-stroke cognitive impairment (PSCI) group (n=6), post-stroke non-cognitive impairment (PSCI) group, Alzheimer's Disease (AD) group (n=6) and normal control group (NC) group (n=6). Different expression miRNA (DE -miRNA) were screened by LIMMA ebayes method, Benjamini-Hochberg check and fold change (P < 0.05, |log2FC|≥1), we construct a DE-miRNA-key gene-signaling pathway network, the roles of DE-miRNA and related genes and signaling pathways in AD and PSCI were deduced through comprehensive network construction and literature search.

2024-04-17 | GSE218605 | GEO

Alzheimer, Mild Cognitive impairment and control samples from AddneuroMed Cohort (batch 2)

Project description:Alzheimer case-control samples originate from the EU funded AddNeuroMed Cohort, which is a large cross-European AD biomarker study relying on human blood as the source of RNA. The design is case-control. Cases are either Alzheimer's disease patients, subjects with mild cognitive impairment or age and gender matched controls.

2015-08-05 | E-GEOD-63061 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data